ストックスクリーナーアプリを入手
13.44
9.32%
1.045
前日終値:
$12.39
開ける：
$12.36
24時間の取引高:
108.58K
Relative Volume:
0.57
時価総額：
$293.72M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+35.77%
1か月 パフォーマンス:
+29.05%
6か月 パフォーマンス:
+13.39%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$12.32
$13.77
1週間の範囲:
$9.18
$13.77
52週間の値動き範囲:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
名前
Aardvark Therapeutics Inc
セクター
電話
(858) 225-7696
住所
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
AARD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
13.49 | 269.99M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.29 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
721.77 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.94 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
896.34 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.94 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-03 | 開始されました | Raymond James | Strong Buy |
| 2025-11-07 | 開始されました | BTIG Research | Buy |
| 2025-09-29 | 開始されました | Stifel | Buy |
| 2025-06-30 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-10 | 開始されました | BofA Securities | Buy |
| 2025-03-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-10 | 開始されました | Morgan Stanley | Overweight |
| 2025-03-10 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Aardvark Therapeutics Inc (AARD) 最新ニュース
Will Aardvark Therapeutics Inc. stock benefit from commodity pricesMarket Growth Report & Daily Market Momentum Tracking - Newser
Raymond James Financial Begins Coverage on Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat
Individual investors among Aardvark Therapeutics, Inc.'s (NASDAQ:AARD) largest shareholders, saw gain in holdings value after stock jumped 23% last week - simplywall.st
AARD: Phase 3 Prader-Willi data expected Q3 2026; obesity program readout by end of next year - TradingView
Aardvark Therapeutics initiated with a Strong Buy at Raymond James - TipRanks
Raymond James initiates coverage on Aardvark Therapeutics stock with Strong Buy - Investing.com UK
Aardvark Therapeutics Hosts Investor Webinar on Drug Programs - MSN
Analysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) PT at $30.63 - Defense World
What risks investors should watch in Aardvark Therapeutics Inc. stockEarnings Trend Report & Real-Time Chart Breakout Alerts - BỘ NỘI VỤ
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December - The Manila Times
Why Aardvark Therapeutics Inc. stock is seen as undervalued2025 Big Picture & Fast Gain Swing Alerts - newser.com
Will Aardvark Therapeutics Inc. stock attract ESG investorsJuly 2025 Short Interest & Stepwise Entry/Exit Trade Alerts - newser.com
From HERO To POWER: AARD Charts Bold Course In Obesity And Rare Disease Trials - RTTNews
Real time social sentiment graph for Aardvark Therapeutics Inc. - newser.com
Aardvark Therapeutics Reports Q3 2025 Financial Results - TipRanks
Is Aardvark Therapeutics Inc. forming a reversal patternGold Moves & Reliable Entry Point Alerts - newser.com
RBC Capital Maintains Aardvark Therapeutics (AARD) Outperform Recommendation - Nasdaq
Cantor Fitzgerald reiterates Overweight rating on Aardvark Therapeutics stock By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Aardvark Therapeutics stock, maintains $24 target - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on Aardvark Therapeutics stock - Investing.com
Can Aardvark Therapeutics Inc. stock deliver sustainable ROEMarket Performance Report & Verified Momentum Stock Watchlist - Fundação Cultural do Pará
Aardvark Therapeutics stock price target lowered to $18 at RBC Capital By Investing.com - Investing.com South Africa
Aardvark Therapeutics stock price target lowered to $18 at RBC Capital - Investing.com Nigeria
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates - The Manila Times
Aardvark Therapeutics, Inc. SEC 10-Q Report - TradingView
Aardvark (Nasdaq: AARD) aligns with FDA to lower HERO trial age to 10, runway into 2027 - Stock Titan
Is Aardvark Therapeutics Inc. building a consolidation baseJuly 2025 Sentiment & High Accuracy Buy Signal Tips - newser.com
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Aardvark Therapeutics (NASDAQ: AARD) grants 4,881-share inducement option at $10.44 - Stock Titan
Aardvark Therapeutics, Inc.: Undervalued Potential in the Obesity Treatment Market with Promising Pipeline - TipRanks
Is Aardvark Therapeutics Inc. forming a bottoming basePortfolio Gains Summary & Free Expert Verified Stock Movement Alerts - newser.com
Aardvark Therapeutics Showcases Obesity Research at ObesityWeek - MSN
Is Aardvark Therapeutics Inc. stock attractive for income investorsWeekly Risk Summary & Safe Capital Growth Stock Tips - newser.com
Aardvark Therapeutics Inc (AARD) 財務データ
Aardvark Therapeutics Inc (AARD) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Aardvark Therapeutics Inc (AARD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Jones Bryan | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,250 |
5,300 |
1,250 |
| Lee Tien-Li | Chief Executive Officer |
Sep 15 '25 |
Buy |
9.66 |
10,000 |
96,624 |
1,543,384 |
0.68%
0.99%
大文字化:
|
ボリューム (24 時間):